Your browser is no longer supported. Please, upgrade your browser.
Settings
NMRD Nemaura Medical Inc. daily Stock Chart
NMRD [NASD]
Nemaura Medical Inc.
Index- P/E- EPS (ttm)-0.03 Insider Own70.36% Shs Outstand203.58M Perf Week-2.12%
Market Cap211.72M Forward P/E- EPS next Y- Insider Trans- Shs Float61.52M Perf Month5.58%
Income-3.40M PEG- EPS next Q- Inst Own0.01% Short Float0.31% Perf Quarter1.98%
Sales- P/S- EPS this Y-60.20% Inst Trans- Short Ratio1.81 Perf Half Y-47.47%
Book/sh0.02 P/B52.00 EPS next Y- ROA-61.60% Target Price- Perf Year-74.13%
Cash/sh0.02 P/C42.34 EPS next 5Y- ROE-108.80% 52W Range0.80 - 4.08 Perf YTD15.56%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-74.50% Beta-
Dividend %- Quick Ratio3.90 Sales past 5Y- Gross Margin- 52W Low30.00% ATR0.05
Employees8 Current Ratio3.90 Sales Q/Q- Oper. Margin- RSI (14)49.68 Volatility4.32% 5.66%
OptionableNo Debt/Eq0.00 EPS Q/Q-17.40% Profit Margin- Rel Volume1.01 Prev Close1.03
ShortableNo LT Debt/Eq0.00 Earnings- Payout- Avg Volume106.30K Price1.04
Recom- SMA200.21% SMA50-2.54% SMA200-40.07% Volume107,888 Change0.97%
Apr-16-19 09:15AM  Nemaura Announces Addition of New Predictive Alert Functionality to SugarBEAT® GlobeNewswire
Mar-28-19 08:30AM  Nemaura CEO Provides Update to Shareholders GlobeNewswire
Mar-12-19 09:18AM  Nemaura Medical Announces Exclusive License and Supply Agreement for SugarBEAT® in the GCC Region GlobeNewswire
Feb-12-19 09:15AM  Nemaura Reports Third Quarter 2018 Financial Results GlobeNewswire -7.94%
Feb-11-19 08:00AM  Nemaura Announces Dr. Fred Schaebsdau to Lead Strategy and Business Development GlobeNewswire +22.33%
Feb-07-19 09:00AM  Nemaura Medical Announces Grant of U.S. Patent for SugarBEAT® Glucose Sensing Algorithm GlobeNewswire -6.42%
Jan-17-19 09:00AM  Nemaura Medical Announces Improvement to SugarBEAT® Continuous Glucose Monitor GlobeNewswire
Dec-21-18 08:00AM  Nemaura Announces Completion of Key Stages of Technical File Review for SugarBEAT® CE Mark Approval GlobeNewswire +11.99%
Dec-20-18 03:37PM  Dawson James Securities Announces Closing of $2.0 Million Offering for Nemaura Medical, Inc. GlobeNewswire
Dec-19-18 08:00AM  Nemaura to Host Investor Webinar on December 21 to Provide Update on Recent Developments GlobeNewswire
Dec-18-18 02:01PM  Why Micro Cap Nemaura Medical Crashed 39.5% Today Motley Fool -39.22%
09:00AM  Nemaura Publishes Positive Data from SugarBEAT® FDA Clinical Trial GlobeNewswire
08:40AM  Nemaura Medical Announces Pricing of Up to $2.5 Million Public Offering GlobeNewswire
Dec-17-18 05:15PM  Nemaura Medical Announces Proposed Public Offering GlobeNewswire
Dec-12-18 08:00AM  Nemaura to Present SugarBEAT® Clinical Performance Poster at ATTD, Berlin GlobeNewswire -12.26%
Dec-04-18 08:00AM  Nemaura Successfully Completes Clinical Studies for SugarBEAT® FDA De-Novo 510(k) Submission GlobeNewswire
Nov-20-18 08:00AM  Nemaura Signs License and Distribution Agreement for SugarBEAT® Commercial Launch in Qatar GlobeNewswire
Nov-14-18 09:00AM  Nemaura Medical to Present at the Canaccord Genuity Medical Technologies & Diagnostics Forum GlobeNewswire -5.04%
Nov-12-18 09:00AM  Nemaura Medical to Present at the Stifel 2018 Healthcare Conference GlobeNewswire
Nov-08-18 09:00AM  Nemaura Medical Inc. Reports Second Quarter 2018 Financial Results GlobeNewswire +6.38%
Nov-07-18 09:00AM  Nemaura Successfully Develops Predictive Algorithms and Alarm Functionality for Continuous Glucose Monitor SugarBEAT® GlobeNewswire
Oct-22-18 08:00AM  Nemaura to Host Investor Webinar on October 23rd 2018 to Provide Update on Recent Developments GlobeNewswire +6.10%
Sep-25-18 08:00AM  Nemaura Reports Positive Zero Finger-Stick Calibration Data for SugarBEAT® Continuous Glucose Monitor GlobeNewswire
Sep-18-18 08:00AM  Nemaura Signs Letter of Intent for SugarBEAT® Commercial Launch in Qatar GlobeNewswire +5.83%
Sep-13-18 09:19AM  Why Micro Cap Nemaura Medical Skyrocketed 32% Yesterday Motley Fool +19.93%
Sep-12-18 08:00AM  Nemaura Reports Positive Interim Data from Clinic Portion of SugarBEAT® FDA Clinical Trial GlobeNewswire +32.69%
Aug-09-18 08:00AM  Nemaura Medical Inc. Reports First Quarter 2018 Financial Results GlobeNewswire
Jul-31-18 08:00AM  Nemaura Initiates US FDA Studies, and Reports Positive Interim Data from Home-Use Portion of Study GlobeNewswire +6.94%
Jul-17-18 08:00AM  Nemaura Places SugarBEAT® Manufacturer Order for UK Commercial Launch Business Wire +13.53%
Jun-13-18 09:30AM  Nemaura Medical Inc. Reports Full Year Financial Results Business Wire +8.98%
May-30-18 09:30AM  Nemaura Medical Signs Joint Collaboration Agreement for European Commercialization Business Wire
May-15-18 09:30AM  Nemaura Medical to Present at the UBS Global Healthcare Conference Business Wire
Apr-09-18 09:30AM  Nemaura Medical Appoints Bashir Timol Chief Business Officer Business Wire +23.37%
Mar-28-18 11:05AM  Nemaura Medical Appoints The Ruth Group as Investor and Public Relations Counsel Business Wire
Mar-06-18 09:00AM  Nemaura Medical to Ring the Nasdaq Closing Bell Business Wire
Mar-05-18 10:50AM  CORRECTING and REPLACING -- Nemaura Medical Inc. (Nasdaq: NMRD) to Ring The Nasdaq Stock Market Closing Bell GlobeNewswire
10:00AM  Nemaura Medical Inc. (Nasdaq: NMRD) to Ring The Nasdaq Stock Market Closing Bell GlobeNewswire
Mar-01-18 04:18PM  Nemaura Announces Expansion of Manufacturing Capabilities for SugarBEAT® Commercial Launch Business Wire
Feb-09-18 01:17PM  Nemaura Medical Inc. Reports Third Quarter 2017 Financial Results Business Wire
Jan-31-18 01:20PM  Nemaura Announces Positive Results for its SugarBEAT® European Clinical Program Business Wire +7.24%
Jan-23-18 09:00AM  Nemaura Medical Inc. Announces Uplisting to NASDAQ Capital Market on January 25, 2018 Business Wire +6.38%
Dec-21-17 10:00AM  Nemaura Announces Completion of SugarBEAT® European Clinical Trial Programme and Positive Interim Results Business Wire
Dec-06-17 09:00AM  Nemaura Announces Successful SugarBEAT® Interim Precision Study Results Business Wire
Nov-02-17 09:47AM  Nemaura Medical Inc. Reports Second Quarter 2017 Financial Results Business Wire
Sep-26-17 09:00AM  WallStreet Research Announces Availability of Corporate Profile Coverage on Nemaura Medical, Inc. Business Wire
Sep-21-17 09:00AM  Nemaura Announces Successful Interim Results for SugarBEAT® European Clinical Trials Business Wire
Aug-29-17 11:24AM  Nemaura Develops Medical Grade SugarBEAT® Android App for Diabetes Management Business Wire
Aug-15-17 12:47PM  Nemaura Signs Heads of Terms for sugarBEAT® with Device Technologies for Australia and New Zealand Business Wire
Aug-09-17 09:00AM  Nemaura Medical Inc. Reports First Quarter 2017 Financial Results Business Wire
Aug-03-17 09:00AM  Nemaura Appoints Thomas Moore to Board of Directors as Independent Director Business Wire -14.58%
Nemaura Medical Inc., a medical technology company, discovers, develops, and commercializes specialty medical devices. It provides sugarBEAT, a non-invasive continuous glucose monitoring device for use by persons with Type I and Type II diabetes, as well as for screening pre-diabetic patients. The company was founded in 2009 and is headquartered in Loughborough, the United Kingdom.